Opinion: Insurance companies should pay patients when they make cost-effective health care choices
Stat News • 2/10/2026
Summary
Insurance companies should pay patients when they make cost-effective health care choices. When patients pay the same regardless of the health care option they choose, there is no incentive for them to make judicious choices.
Advertisement
Lindy Score Breakdown (V4.2)
52d
Age
1
Sources
from cluster
1255
Hours Since Seen
Final Score0/100
CategoryAntiLindy
StatusArchived
Recency Multiplier0% (0.5^1255/48)
Hero EligibleNo
Score is 0 because recency decay (0.5^1255/48 = 0.000000) reduced it below 0.5
Score BreakdownRisk 50
Source Reputation: Low-trust source (4/20 pts)
Consensus: Single source - no independent confirmation yet
Age: 52 days - proven survivor
Stories gain Lindy status through source reputation, network consensus, and time survival.
Breaking Similar stories
Opinion: Medical misinformation wins when patients can’t see their doctors
Stat News • 1 day ago
Opinion: Medicare is restricting care for 1 million Americans based on a faulty assumption. Congress must intervene
Stat News • 2 days ago
STAT+: How health care could gum up Trump’s reconciliation push
Stat News • 1 day ago
Opinion: Subscription pricing could expand access to HIV prevention breakthrough while controlling costs
Stat News • Today
Opinion: My patient would rather take a peptide than a statin. That reveals an uncomfortable truth in medicine
Stat News • Today
STAT+: White House proposes 12% cut to federal health agencies in 2027 budget request
Stat News • Today
Opinion: Medical marijuana should not be recommended for PTSD, anxiety, or depression
Stat News • 2 days ago
Opinion: STAT+: Cardiology’s finally prioritizing prevention — but what will it look like?
Stat News • 1 day ago
STAT+: Can a psychedelic ‘coach’ make ketamine therapy even more effective?
Stat News • 2 days ago
Eli Lilly’s obesity pill approved by FDA, setting up fierce competition with Novo Nordisk
Stat News • 2 days ago
Anti-Lindy Similar stories
STAT+: Pharmalittle: We’re reading about a Merck acquisition, the rise of former Loxo execs at Lilly, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about an FDA OK for a rare disease drug, a grilling of the PTO chief, and more
Stat News • 1 week ago
STAT+: Pharmalittle: We’re reading about Trump pushing drug pricing policy, Chinese biotech licensing, and more
Stat News • 4 days ago
STAT+: FDA approves Denali Therapeutics drug for Hunter syndrome
Stat News • 1 week ago